Jacobs Levy Equity Management
KNTE

Jacobs Levy Equity Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Jacobs Levy Equity Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-449,453
Closed -$629K – 1099
2023
Q3 		$629K Buy
449,453
+345,572
+333% +$830K ﹤0.01% 757
2023
Q2 		$315K Buy
+103,881
New +$400K ﹤0.01% 872

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management's KNTE Position: Q4 2023 in Review

Jacobs Levy Equity Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 449,453 shares — an estimated $629K sold.

Jacobs Levy Equity Management first reported a position in KNTE in Q2 2023 and held it in 2 quarters. The position peaked at $629K in Q3 2023. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • Jacobs Levy Equity Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 449,453 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $629K.
  • Jacobs Levy Equity Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2023 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Kinnate Biopharma Inc. Common Stock position peaked at $629K in Q3 2023.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2023, filed 14 Feb 2024.